Topical Alpha-1 Agonist Nipple Stimulation for Sexual Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for female sexual dysfunction (FSD) are limited and often associated with negative side effects, and there is a need for alternative methods to enhance female sexual satisfaction, particularly targeting the arousal and desire phases of the female sexual response cycle.
Innovation Solution
A method involving the topical application of a therapeutically effective amount of an alpha-1 adrenergic receptor agonist, such as phenylephrine, to the nipple-areola complex to treat FSD, enhance sexual satisfaction, and increase oxytocin release, thereby addressing symptoms like reduced sexual interest, arousal, and orgasm duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormonal or psycho-affective drugs are used to treat FSD, then sexual desire and arousal are improved, but serious negative side effects occur
Solution Approach 1:
The patent uses oxytocin as an intermediary substance that mediates between nipple stimulation and sexual arousal. Instead of directly administering hormones or psycho-affective drugs, the invention stimulates endogenous oxytocin release through nipple-areola complex stimulation, which then acts as a natural mediator to enhance sexual desire and arousal without the harmful side effects of exogenous drugs
Solution Approach 2:
The invention enables the body's self-service mechanism by stimulating endogenous oxytocin production through nipple-areola complex stimulation. Rather than relying on external hormonal or psycho-affective drugs, the body produces its own oxytocin naturally in response to stimulation, creating a self-regulating therapeutic effect that avoids drug-induced side effects
2Adaptability or versatility
If alpha-1 adrenergic receptor agonists are applied to hair-bearing skin, then hair erection is achieved, but application to nipple-areola complex for FSD treatment is unexpected and unproven
Solution Approach 1:
The patent applies local quality by targeting the nipple-areola complex specifically rather than applying the agonist systemically or to other areas. The alpha-1 adrenergic receptor agonist is applied locally to the nipple-areola complex where it can stimulate smooth muscle contraction and enhance sensitivity in that specific region, which then triggers endogenous oxytocin release. This localized application provides both the mechanical stimulation effect and the systemic hormonal response without widespread drug exposure
Solution Approach 2:
The invention uses preliminary action by applying the alpha-1 adrenergic receptor agonist to the nipple-areola complex before sexual activity to pre-stimulate the area and trigger oxytocin release in advance. This preliminary stimulation prepares the physiological state for enhanced sexual arousal and desire, creating a primed state that facilitates subsequent sexual activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively increases nipple sensitivity, reduces time to orgasm, and enhances sexual satisfaction by mimicking the effects of sympathetic neuron activation, providing a potential alternative to existing hormonal and psycho-affective treatments with fewer side effects.
Implementation Method 1
A1AR agonists bind to α1-receptors on vascular smooth muscle and induce smooth muscle cell contraction, thus mimicking the effects of sympathetic neurons activation of smooth muscles via adrenergic receptors
Implementation Method 2
US Patent Application Pub. 2004/0198706 (Carrara et al.) discloses formulations for providing transdermal or transmucosal delivery of active agents
Data Source
AI summary
Compositions and methods for treating sexual dysfunction and enhancing sexual satisfaction using topical application of a therapeutic agent such as an alpha-1 adrenergic receptor agonist to the nipple-areola complex are disclosed.